Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

Orally Disintegrating Tablets: Potentials in Psychiatry

Oleneva E.V., Ryvkin P.V., Ladyzhenskij M.Ya., Mosolov S.N.
Federal Medical Research Center for Psychiatry and Narcology by the name of V.P.Serbsky Minzdrava RF

Summary: The review examines the main ideas about the bioavailability and bioequivalence of drugs, as well as various aspects related to the practical use of orally disintegratable forms of psychotropic drugs, their disadvantages, advantages, features of pharmacokinetics and biotransformation. The issues of the impact of this method of administration of drugs on compliance and the effectiveness of therapy in general, using the results of clinical studies and statistical modeling, are highlighted.

References: 
  • 1. Klinicheskaya farmakologiya:uchebnik / pod red. V.G. Kukesa. – Izd. 3-e, pererab. – M.: GEOTAR-Media, 2006. – 944 s.
  • 2. Klinicheskaya farmakologiya: uchebnik / pod red. V.G. Kukesa. – Izd. 4-e, pererab. – M.: GEOTAR-Media, 2009. –1056 s. (1)
  • 3. Pharmeuropa. – 1998, dek. – T. 10, № 4. – S. 547.
  • 4. San L., Casillas M., A.Ciudad, I.Gilaberte. Dispergiruemye tabletki olanzapina: obzor effektivnosti i komplaensa (referat) // Psihiatriya i psihofarmakoterapiya imeni P.B. Gannushkina. – 2011. – № 4. – S. 51–58.
  • 5. Markowitz J., DeVane C., Malcolm R., Gefroh A., Wang J., Zhu J., Donovan L. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers // J Clin Pharmacol. – 2006, Feb. – Vol. 46 (2). – P. 164–171.
  • 6. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second‐generation antipsychotic. // International Journal of Clinical Practice // 2009, Dec. – Vol. 63, Iss.12. – P. 1762–1784. – DOI: 10.1111/j.1742-1241.2009.02228.x
  • 7. Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennyh sredstv (formulyarnaya sistema) / pod red. A.G. Chuchalina.– Vyp. IV (12-e izd., pererab. i dop.). – Moskva, 2011.
  • 8. Hirani J., Rathod D., Vadalia K. Orally Disintegrating Tablets: A Review // Tropical Journal of Pharmaceutical Research. – 2009. – Vol. 8 (2). – P. 168–172.
  • 9. Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennyh sredstv (formulyarnaya sistema) / pod red. A.G. Chuchalina. – Vyp. IV. – Moskva, 2003.
  • 10. Sreenivas S., Dandagi P., Gadad A., Godbloe A., Hiremath S., Mastiholimath, V. Orodispersible tablets: New-fangled drug delivery systems – A review // Indian Journal of Pharmaceutical Education and Research. – 2005. – Vol. 39 (4). – P. 177–181.
  • 11. Seager H. Drug-delivery Products and the Zydis Fast-dissolving Dosage Form // Journal of Pharmacy and Pharmacology. – 1998. – Vol. 50 (4). – P. 375–382.
  • 12. Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennyh sredstv (formulyarnaya sistema) / pod red. A.G. Chuchalina. – Vypusk XVIII. – Moskva, 2017.
  • 13. Mogilyuk V.V. Oral'no dezintegriruemye tabletki: biofarmacevticheskie aspekty // Provizor. –2009. – № 1–2. – S. 32–35.
  • 14. Klinicheskaya farmakologiya: uchebnik / pod red. V.G. Kukesa – Izd. 2-e, pererab. Moskva, 2004. – 528 c.
  • 15. Kozlova Zh.M., Zabolotnaya P.G., Maslova M.N. Bystrodispergiruemye oral'nye sistemy dostavki // Novaya nauka: ot idei k rezul'tatu. – 2015. – № 2. – S. 75–78.
  • 16. Ghosh T., Pfister W. Drug Delivery to the Oral Cavity. – Boca Raton: Taylor & Francis, 2005. – 414 p.
  • 17. Bekker R.A., Bykov Yu.V. Novye vozmozhnosti terapii psihicheskih i somaticheskih zabolevanij s ispol'zovaniem preparata Eliceya® Ku-Tab® (obzor literatury) // Psihiatriya i psihofarmakoterapiya. – 2017. – № 19 (4)yu – S. 51–60.
  • 18. Brown D. Orally disintegrating tablets: Taste over speed // Drug Deliv Tech. – 2001. – Vol. 3 (6). – P. 58–61.
  • 19. Mosolov S.N., Cukarzi E.E., Kapiletti S.G. Antipsihoticheskaya farmakoterapiya shizofrenii: ot nauchnyh dannyh k klinicheskim rekomendaciyam // Biologicheskie metody terapii psihicheskih rasstrojstv. Dokazatel'naya medicina – klinicheskoj praktike. / pod red. S.N. Mosolova. – M.: Social'no-politicheskaya mysl', 2012. – S. 11–61.
  • 20. Potkin S., Cohen M., Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial // J Clin Psychiatry. – 2007. – Vol. 68. – P. 1492–1500.
  • 21. GOST R 57679–2017. Lekarstvennye sredstva dlya medicinskogo primeneniya. Issledovaniya bioekvivalentnosti lekarstvennyh preparatov. Data vvedeniya 01.08.2018.
  • 22. Maher E. et al. In vitro/in vivo evaluation of an optimized fast dissolving oral film containing olanzapine coamorphous dispersion with selected carboxylic acids // Drug Delivery. – 2016. – Vol. 23 (8). – P. 3088–3100.
  • 23. Cilurzo F., Cupone I.E., Minghetti P., Buratti S., Gennari C.G.M., Montanari L.. Diclofenac fastdissolving film: suppression of bitterness by a tastesensing system // Drug Dev Ind Pharm. – 2011. – Vol. 37, No. 3. – P. 252–259.
  • 24. Shevchenko A.M. Metodologicheskie aspekty razrabotki tekhnologii tverdyh bystrorastvorimyh lekarstvennyh form: avtoref. dis. … d-ra farm. nauk. – M., 2009. – 43 s.
  • 25. Bhowmik D., Chiranjib B., Pankaj K., Chandira R.M. Fast Dissolving Tablet: An Overview // Journal of Chemical and Pharmaceutical Research. – 2009. – No. 1 (1). – R. 163–177.
  • 26. Chue P., Jones B., Adams C. Use of olanzapine rapidly-disintegrating tablet in schizophrenia. – American College of Neuropsychopharmacology (ACNP) Annual Meeting, Las Croabas, Puerto Rico, 14–18 December 1999 (Conference Proceedings). – 2001.
  • 27. Preethi S., Selviarun K., Jagadeesh S., Nagendre R., Prashanth Kumar M.R. Oral dispersible tablet -an overview // Int J Inv Pharm Sci. – 2013. – No. 1 (5). – R. 438–447.
  • 28. Shirsand B at al. Design and Evaluation of Fast Dissolving Tablets of Clonazepam // Indian J Pharm Sci. – 2008, Nov.–Dec. – Vol. 70 (6). – P. 791–795. – DOI: 10.4103/0250-474X.49125
  • 29. Shevchenko A.M., Kovalevskaya E.G.. Tekhnologicheskie osobennosti razrabotki sostava i sposobov proizvodstva orodispersnyh lekarstvennyh form // Razrabotka i registraciya lekarstvennyh sredstv. – 2014. – № 6. – S. 30–34.
  • 30. Biologicheskie metody terapii psihicheskih rasstrojstv. Dokazatel'naya medicina – klinicheskoj praktike / pod red. S.N. Mosolova. – M.: Social'no-politicheskaya mysl', 2012. – 1073 s.
  • 31. Normann C., Schmauss M., Bakri N., Gerwe M., Schreiner A. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets // Pharmacopsychiatry. – 2006. – Vol. 39 (6). – P. 209–212.
  • 32. Kinon B., Hill A., Liu H., Kollack-Walker S. Dispergiruemye (rastvorimye vo rtu) tabletki olanzapina v terapii ostryh psihozov u bol'nyh shizofreniej s neudovletvoritel'noj komplaentnost'yu (rasshirennyj referat) // Psihiatriya i psihofarmakoterapiya imeni P.B. Gannushkina. – 2006. – № 4. – S. 83–84.
  • 33. Weiden P., Rapkin B., Mott T. et al. Rating of medication influences (ROMI) scale in schizophrenics // Schizophrenia Bull. – 1994. Vol. 20. – P. 297–310.
  • 34. Weiden P.J., Mott T., Curcio N. Recognition and management of neuroleptic noncompliance // Shriqui C., Nasrallah H. (eds.). Contemporary Issues in the Treatment of Schizophrenia. – Washington, DC: American Psychiatric Press, 1995. – P. 463–485.
  • 35. Perry P.J., Sanger T., Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients // J Clin Psycho-pharmacol. – 1997. Vol. 17. – P. 472–477.
  • 36. Barrett R. et al. Oxazepam premedication in neurosurgical patients // The use of a fastdissolving oral preparation of oxazepam as a pre-operative anxiolytic drug in neurosurgical patients Anaesthesia. – 1984. – Vol. 39. – P. 429–432.
  • 37. Rajni B., Sushil Kh., Pravin P. Design Optimization and In Vitro - In Vivo Evaluation of Orally Dissolving Strips of Clobazam // Journal of Drug Delivery. – 2014. – Article ID 392783. – 15 p.
  • 38. Jatinderpal S., Rajeev G., Ghanshyam Das G.. Enhancement of Solubility of Lamotrigine by Solid Dispersion and Development of Orally Disintegrating Tablets Using Full Factorial Design // Journal of Pharmaceutics. – 2015. – Article ID 828453. – 8 p.
  • 39. Abed Kh.K., Hussein A.A., Ghareeb M.M., Abdulrasool A.A. Formulation and Optimization of Orodispersible Tablets of Diazepam // AAPS PharmSciTech. – 2010, March. – Vol. 11, No. 1. – P. 356–361.
  • 40. Van de Velde A., Camu F. Efficacy of lorazepam oral fast dissolving drug formulation (FDDF) in anesthesia premedication in adults: a double-blind placebo controlled comparison // Acta Anaesthesiol Belg. – 1988. Vol. 39 (2). – P. 95–100.
  • 41. Bharat Damle, Sanela Tarabar, Uma Kuruganti, Penelope Crownover, Robert R LaBadie. Bioequivalence of Alprazolam Sublingual Tablet Formulation and Alprazolam Immediate Release Tablet in Healthy Volunteers // Journal of Bioequivalence & Bioavailability. – 2013. – Vol. 5 (4). – P. 149–153.
  • 42. Klonopin (clonazepam) wafers NDA 020813. FDA Approved Labeling Text. 2013, Oct. – URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017533s053,020... (accessed 12.06.2018).
  • 43. A multicenter, open-label, randomized crossover trial to assess subject preference for alprazolam orally disintegrating tablets compared to conventional alprazolam tablets in subjects with anxiety. – CT registry ID#: NCT00139854. – Study no.: SP829 Clinical study summary (CSS). – Approved by UCB 19 Nov 2008.